Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Nivolumab + Axitinib for Advanced Melanoma
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing a new combination therapy for melanoma that has progressed despite prior treatment. The new therapy consists of two drugs given intravenously and by mouth, respectively. Patients may continue on the therapy for up to two years if it is well tolerated and effective.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service